Ticker > Company >

Glenmark Pharma share price

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK BSE: 532296 SECTOR: Pharmaceuticals & Drugs  260k   1k   222

1670.90
+33.10 (2.02%)
BSE: 13 Jun 04:01 PM

Price Summary

Today's High

₹ 1673.75

Today's Low

₹ 1605.5

52 Week High

₹ 1830.05

52 Week Low

₹ 1199.95

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

47152.93 Cr.

Enterprise Value

47681.02 Cr.

No. of Shares

28.22 Cr.

P/E

29.28

P/B

1.92

Face Value

₹ 1

Div. Yield

0.15 %

Book Value (TTM)

₹  868.32

CASH

129.15 Cr.

DEBT

657.24 Cr.

Promoter Holding

46.65 %

EPS (TTM)

₹  57.06

Sales Growth

-4.01%

ROE

25.3 %

ROCE

32.59%

Profit Growth

327.48 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Glenmark Pharmaceuticals Ltd.

CANDID ALEX-P SYRUP SIBUTRIM GLINATE LEREZ VORTH-XT STRONAT ERDOZET DYCERIN FINTOP SIBET NITAZET-O ONABET ESOZ - D COLY-MONAS PALNOX AIRTEC-FB BORTRAC GEFTIB TAZRET EVERMIL GLUCAR ZINOX TACROZ FORTE FLEXILOR MIGNAR ASCORIL PLUS TACROZ

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-4.01%
3 Year1.4%
5 Year4.59%

Profit Growth

1 Year327.48%
3 Year46.32%
5 Year26.08%

ROE%

1 Year25.3%
3 Year14.99%
5 Year13.5%

ROCE %

1 Year32.59%
3 Year18.14%
5 Year15.64%

Debt/Equity

0.0286

Price to Cash Flow

-95.17

Interest Cover Ratio

26.2634

CFO/PAT (5 Yr. Avg.)

0.440963595563448

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 46.65 0.00
Dec 2024 46.65 0.00
Sep 2024 46.65 0.00
Jun 2024 46.65 0.00
Mar 2024 46.64 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 46.3215135497746% for the Past 3 years.
  • The company has significantly decreased its debt by 2499.164 Cr.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 26.2634.
  • Company’s PEG ratio is 0.08942075779885.
  • The company has an efficient Cash Conversion Cycle of -137.5008 days.

 Limitations

  • The company has shown a poor revenue growth of 1.40367877643066% for the Past 3 years.
  • Company has negative cash flow from operations of -495.45.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 2148.22 2329.54 2636.1 2251.28 2009.49
Total Expenditure 1650.78 1698.44 1857.47 1757.35 1668.97
Operating Profit 497.45 631.1 778.63 493.93 340.53
Other Income 786.27 55.65 83.08 129.19 88.45
Interest 83.39 15.35 11.8 8.46 13.13
Depreciation 52.4 53.09 54.85 55.16 55.53
Exceptional Items 5146.91 0 0 0 -179.17
Profit Before Tax 6294.85 618.31 795.06 559.49 181.16
Tax 1681.15 164.58 200 145.69 33.4
Profit After Tax 4613.7 453.73 595.06 413.8 147.76
Adjusted EPS (Rs) 163.5 16.08 21.09 14.66 5.24

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 6712.63 7567.93 8141.58 8220.66 7891.12
Total Expenditure 5408.4 5677.59 6453.36 6747.9 6649.46
Operating Profit 1304.23 1890.34 1688.22 1472.77 1241.66
Other Income 606.79 396.24 614.63 985.94 1168.02
Interest 256.39 265.9 236.04 206.82 277.11
Depreciation 138.54 150.82 159.7 184.15 202.16
Exceptional Items 18.55 73.89 430.33 -495.87 5070.33
Profit Before Tax 1534.64 1943.76 2337.45 1571.87 7000.75
Tax 180.1 294.31 339.66 363.11 1833.46
Net Profit 1354.55 1649.45 1997.79 1208.77 5167.29
Adjusted EPS (Rs.) 48 58.46 70.8 42.84 183.11

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 28.22 28.22 28.22 28.22 28.22
Total Reserves 13198.05 14781.29 16710.37 17849.25 22942.4
Borrowings 3131.17 3112.58 2571.74 2660.82 0
Other N/C liabilities 389.35 1150.51 1412.85 2394.32 3286.93
Current liabilities 2991.54 3934.34 4896.21 3991.95 5152.18
Total Liabilities 19738.33 23006.93 25619.39 26924.55 31409.72
Assets
Net Block 1611.95 1722.49 1752.33 1745.94 1756.25
Capital WIP 152.5 93.31 101.17 159.07 175.5
Intangible WIP 47.52 38.09 7.87 13.27 22.17
Investments 4713.93 6989.95 8559.39 10332.71 12964.79
Loans & Advances 8182.74 7818.27 9335.01 9934.57 10940.59
Other N/C Assets 2.78 4.72 5.55 3.63 6.18
Current Assets 5026.92 6340.11 5858.08 4735.35 5544.26
Total Assets 19738.33 23006.93 25619.39 26924.55 31409.72
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 1534.64 1943.76 2337.45 1571.87 7000.75
Adjustment -107.18 235.11 -617.5 122.48 -5884.79
Changes in Assets & Liabilities 491.01 -599.61 -113.17 196.13 -740.31
Tax Paid -339.35 -335.84 -390.72 -416.42 -871.1
Operating Cash Flow 1579.12 1243.42 1216.07 1474.06 -495.45
Investing Cash Flow -1607.41 -1235.19 -897.02 -431.52 3197.17
Financing Cash Flow -139.42 -80.79 -305.12 -978.5 -2666.45
Net Cash Flow -167.71 -72.57 13.93 64.05 35.27

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 46.64 46.65 46.65 46.65 46.65
blanche elizabeth saldanh... 0.39 0.39 0.39 0.39 0.39
cherylann maria pinto 0.27 0.27 0.27 0.27 0.27
glenn mario saldanha 0.35 0.35 0.35 0.35 0.35
neha saldanha 0.01 0.01 0.01 0.01 0.01
robin joseph pinto 0.18 0.18 0.18 0.18 0.18
saldanha family trust 45.45 45.45 45.45 45.45 45.45
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 53.36 53.35 53.35 53.35 53.35
3p india equity fund 1 - - - 1.02 1.02
ashish dhawan 2.55 2.55 2.55 1.88 1.77
ellipsis partners llc 1.68 1.68 1.31 1.17 1.11
government pension fund g... 3.14 3.25 3.25 3.25 3.25
hdfc mutual fund - hdfc n... - - - - 4.27
invesco india midcap fund... - - 1.07 - 1.41
investor education and pr... - 0.09 0.09 0.09 0.09
mirae asset arbitrage fun... - - - - 3.53
smallcap world fund, inc 3.47 3.13 3.10 3.38 3.21
aditya birla sun life tru... 2.06 1.50 1.15 1.16 -
hdfc mutual fund - hdfc m... 2.54 3.63 - 3.46 -
invesco india manufacturi... - - - 1.17 -
mirae asset large & midca... - - - 3.55 -
hdfc mutual fund-hdfc arb... - - 3.42 - -
mirae asset elss tax save... - - 2.80 - -
icici prudential mnc fund... 1.23 - - - -
investor education and pr... 0.09 - - - -

Annual Reports

Title Action
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY ACTION
Credit CRISIL
Credit CRISIL
Credit INDIA RATINGS & RESEARCH
Credit INDIA RATINGS & RESEARCH
Credit CRISIL
TYPE AGENCY ACTION
Research Report By:
Research HDFC Securities
Research ICICI Securities Limited
Research Motilal Oswal
Research Reliance Securities
Research Prabhudas Lilladhar
Research HDFC Securities
Research Geojit BNP Paribas

Concalls & Presentations

TYPE QUARTER ACTION
Concall Q3FY25
Concall Q3FY25
Concall Q1FY24
TYPE QUARTER ACTION
Presentation Q4FY25
Presentation Q4FY24
Presentation Q3FY24
Presentation Q3FY19
Presentation Q2FY24
Presentation Q1FY24

Company News

Glenmark Pharma Stock Price Analysis and Quick Research Report. Is Glenmark Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Glenmark Pharma and its performance over the period of time. Glenmark Pharma stock price today is Rs 1669.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Glenmark Pharma cash from the operating activity was Rs -495.45 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Glenmark Pharma has a Debt to Equity ratio of 0.0286 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Glenmark Pharma , the EPS growth was 327.4537 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Glenmark Pharma has OPM of 15.734942027867 % which is a good sign for profitability.
     
  • ROE: Glenmark Pharma have a healthy ROE of 25.3032 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Glenmark Pharma is Rs 1669.9. One can use valuation calculators of ticker to know if Glenmark Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Glenmark Pharma
X